BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicin
citrate liposome injection) has received FDA approval for use
as primary therapy for advanced HIV-associated Kaposi's sarcoma
In the company-sponsored phase III trial, conducted at 13 US and
Canadian centers and involving 227 patients with advanced HIV-associated
KS, Dauno-Xome was found to have efficacy comparable to the three-drug
regimen of Adria-mycin, bleomycin, and vincristine (ABV).
Average survival was 342 days for patients on DaunoXome vs 291
days for those on ABV. Side effects such as neu-ropathy and alopecia
were reduced significantly with use of DaunoXome.